Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MCX101
- Development stage
- Preclinical
- Lead developer
- mCureX
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
01
Overview
MCX101 is an mRNA-based vaccine candidate developed by mCureX Therapeutics, a subsidiary of OliX Pharmaceuticals, in collaboration with Samyang Holdings. It is designed to prevent COVID-19 by encoding the SARS-CoV-2 spike (S) protein. Upon administration, the mRNA instructs host cells to produce the spike protein, which subsequently elicits a protective immune response. The vaccine utilizes a drug delivery system provided by Samyang Holdings to protect the mRNA and facilitate its entry into cells. As of the latest reports, MCX101 is in the preclinical development stage, with animal immunogenicity studies underway.
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on MCX101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MCX101.